In this important update, COO and President, Matthew Mills discusses a strategic plan to list the Company on a national exchange to support and bolster the growth of the Nature-Cide and the Thermal-Aid divisions. Matthew Mills also reports on exciting news regarding the Company’s revenue growth, progress with institutional investment firms and the status of the Nature-Cide toxicity testing. Please watch this important announcement.
With the recipe of essential products and services, growing revenue, international distribution positioning, all while negotiating with a handful of investment banking firms, the management team has decided to move forward with the plan to execute an Initial Public Offering.
In order for us to successfully execute this plan, we have to immediately accelerate our internal capital raising efforts to support our ongoing growth with continued inventory needs, our marketing initiative expenditures, supporting our stabilized overhead as well as the cost associated with the accounting and legal teams to position the Company for an IPO. All of this is needed to enable our market entrance in a timely manner. This is a call to action for every shareholder to get involved. We cannot stress enough the importance for all current shareholders to participate in any way they can, to help bridge the gap from a private company to a public entity.
Many of our shareholders have expressed excitement in recent weeks, as our revenue for 2020 has broken out, while mid to large-sized investment banking and family offices show interest in an opportunity for sizable long term international positioning.
With over 3000 shareholders that supported our growth thus far, we know, as a group, we can get this done together. This opportunity has come with a lot of hard work, of which our shareholders have supported the Company every step of the way. We are very excited to have the continued support from everyone who has believed in this mission. It took a village to build this Company and besides having a nice growth spurt going for 2020, it's clear that the size of our investor base is another major attribute of interest to the investment banking community. That said, it's going to take OUR village to help steer, land and pass the baton to these large scale investors in the coming months to continue to fuel our growth potential long term.
If you have questions about this plan of action and or want to learn more of the specifics, please contact our Investor Relations department.
Thank you very much for all of your continued and future support.
Please Click the Invest Now Button
DISCLAIMER AND FORWARD-LOOKING STATEMENTS
The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the Regulation A+ Offering Circular and the New Regulation CF Offering as well as all Securities Exchange Commission filings before making any investment in the Company.
This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.